News - Onconova Therapeutics, Revolade

Filter

Popular Filters

“Breakthrough Therapy” designation for GlaxoSmithKline’s Promacta/Revolade for SAA

“Breakthrough Therapy” designation for GlaxoSmithKline’s Promacta/Revolade for SAA

03-02-2014

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for UK pharma…

GlaxoSmithKlinePharmaceuticalPromactaRare diseasesRegulationRevolade

Onconova drops Ph III trial of rigosertib in pancreatic cancer

20-12-2013

US biopharma company Onconova Therapeutics says it has discontinued the Phase III ONTRAC study of intravenous…

OncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

New Zealand funding plans for Tarceva and Revolade

New Zealand funding plans for Tarceva and Revolade

09-12-2013

Following a consultation, New Zealand’s Pharmaceutical Management Agency PHARMAC said this morning…

Asia-PacificGlaxoSmithKlineHematologyNew ZealandOncologyPharmaceuticalPricingRegulationRevoladeRocheTarceva

Onconova could file NDA for cancer drug rigosertib next year

Onconova could file NDA for cancer drug rigosertib next year

15-11-2013

Analysts at Edison Equity Research have indicated that US biopharma company Onconova Therapeutics (Nasdaq:…

FinancialOncologyOnconova TherapeuticsPharmaceuticalResearchrigosertibUSA

GSK's Revolade recommended by UK's NICE for low blood platelet counts

24-07-2013

The UK's drugs watch dog the National Institute for Health and Care Excellence (NICE) has recommended…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRevolade

Pivotal drivers for prescribing metastatic pancreatic cancer drugs: report

09-07-2013

The effect on key efficacy endpoints, primarily the effect of an emerging therapy on overall survival,…

AbraxaneBiotechnologyCelgeneEli LillyEuropeGemzarMarkets & MarketingNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalrigosertib

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

Five new drugs for myelodysplastic syndromes set to launch by 2018

10-02-2013

Through 2018, five new drugs will launch for the treatment of myelodysplastic syndromes (MDS), three…

BaxterCyclacelEstybonEuropeGlaxoSmithKlineMarkets & MarketingMerck & CoNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalResearchRevoladesapacitabineZolinza

GVK Biosciences and Onconova in cancer drug development deal

09-01-2013

GVK Biosciences, a Hyderabad, India-based contract research and development organization, and privately-held…

Ex-RADGVK BiosciencesON-013105OncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Baxter in up to $565 million deal with Onconova for rigosertib

20-09-2012

US companies Baxter International (NYSE: BAX) and privately-held biotech Onconova Therapeutics have entered…

Baxter InternationalEstybonEuropeLicensingOncologyOnconova TherapeuticsPharmaceuticalrigosertib

Back to top